Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
This report is about education for children with disabilities in South Africa.
The new five-year agenda of WHO in Africa, The Africa Health Transformation Programme, 2015–2020: a vision for universal health coverage, is the strategic framework that will guide WHO’s contribution to the emerging sustainable development platform in Africa. It articulates a vision for health a...nd development that aims to address the unacceptable inequalities and inequities that have kept our region lagging far behind others in terms of health indices and enjoyment of the highest attainable standard of life.
more
Knowledge based upon a descriptive literature review of applied research
The Government of Liberia (GoL) reports three additional EVD cases linked to the Margibi County cluster, including one in Liberia’s Montserrado County; new confirmed case total reaches six
Recently extended Operation Northern Push strengthens contact tracing and EVD prevention activities ...in Sierra Leone
The Government of Guinea (GoG) and EVD response actors investigate source of infection for EVD-positive nurse in Forécariah Prefecture, the area’s first confirmed case among health care workers since March
more
What We Know, What We Don’t Know, and What We Need to Do
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more